Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
At baseline, most patients (97%) were treated with one or more glucose-lowering medications, including metformin (76%), insulin (51%), SGLT-2i (27%), sulfonylurea (29%), and DPP-4i (23%) with CV disease and risk factors managed with lipid-lowering medications (89%), platelet-aggregation inhibitors including aspirin (77%), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (79%), and beta blockers (64%)
Gassmann M, Mairburl H, Livshits L, Hackbusch M, Malczyk M, Kraut S, et al
Sheng B, Gao S, Chen X, Liu Y, Lai N, Dong J, Sun J, Zhou Y, et al
10.1007/s00726-008-0202-y 200 StockwellB
the caloric deficit converts that opportunity into actual results
PMCID: PMC2645018
